Skip to main content
main-content

12.08.2016 | Original Article – Cancer Research | Ausgabe 10/2016

Journal of Cancer Research and Clinical Oncology 10/2016

11a-N-Tosyl-5-deoxi-pterocarpan, LQB-223, a novel compound with potent antineoplastic activity toward breast cancer cells with different phenotypes

Zeitschrift:
Journal of Cancer Research and Clinical Oncology > Ausgabe 10/2016
Autoren:
Lauana Greicy Tonon Lemos, Gabriela Nestal de Moraes, Deborah Delbue, Flavia da Cunha Vasconcelos, Paula Sabbo Bernardo, Eric W–F. Lam, Camilla Djenne Buarque, Paulo Ribeiro Costa, Raquel Ciuvalschi Maia
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s00432-016-2212-6) contains supplementary material, which is available to authorized users.

Abstract

Multidrug resistance is the major obstacle for successful treatment of breast cancer, prompting the investigation of novel anticancer compounds.

Purpose

In this study, we tested whether LQB-223, an 11a-N-Tosyl-5-deoxi-pterocarpan newly synthesized compound, could be effective toward breast cancer cells.

Methods

Human breast cell lines MCF-7, MDA-MB-231, HB4a and MCF-7 DoxR were used as models for this study. Cell culture, MTT and clonogenic assay, flow cytometry and Western blotting were performed.

Results

The LQB-223 decreased cell viability, inhibited colony formation and induced an expressive G2/M arrest in breast cancer cells. There was an induction in p53 and p21Cip1 protein levels following treatment of wild-type p53 MCF-7 cells, which was not observed in the mutant p53 MDA-MB-231 cell line, providing evidence that the compound might act to modulate the cell cycle regardless of p53 status. In addition, LQB-223 resulted in decreased procaspase levels and increased annexin V staining, suggesting that the apoptotic cascade is also triggered. Importantly, LQB-223 treatment was shown to be less cytotoxic to non-neoplastic breast cells than docetaxel and doxorubicin. Strikingly, exposure of doxorubicin-resistant MCF-7-DoxR cells to LQB-223 resulted in suppression of cell viability and proliferation in levels comparable to MCF-7. Of note, MCF-7-DoxR cells have an elevated expression of the P-glycoprotein efflux pump when compared to MCF-7.

Conclusion

Together, these results show that LQB-223 mediates cytotoxic effects in sensitive and resistant breast cancer cells, while presenting low toxicity to non-neoplastic cells. The new compound might represent a potential strategy to induce toxicity in breast cancer cells, especially chemoresistant cells.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary material 1 (DOC 22 kb)
432_2016_2212_MOESM1_ESM.doc
Supplementary material 2 (PDF 648 kb)
432_2016_2212_MOESM2_ESM.pdf
Supplementary material 3 (PDF 307 kb)
432_2016_2212_MOESM3_ESM.pdf
Supplementary material 4 (PDF 246 kb)
432_2016_2212_MOESM4_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 10/2016

Journal of Cancer Research and Clinical Oncology 10/2016 Zur Ausgabe

Original Article – Clinical Oncology

Telangiectatic osteosarcoma: a review of 87 cases

  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise